With a significant reduction in the number of migraine days, average headache days per month and headache-associated disability, Fremanezumab exhibits considerable outcomes over placebo in 12-week trial. It was a double-blind, randomized, placebo-controlled, phase 3 trial, conducted to assess the efficacy, side-effect and safety profile of two subcutaneous dose treatment of Fremanezumab in preventing chronic migraine.

Selected patients were randomized to receive Fremanezumab quarterly (625 mg medication at baseline and placebo at 4 and 8 week), monthly (625 mg medication at baseline and 225 mg at 4 and 8 week) or matching placebo subcutaneously. Following treatment, Fremanezumab monthly exhibited significant a reduction in headache days per month followed by Fremanezumab quarterly and placebo. Five patients from each Fremanezumab and three from placebo group found with abnormalities in hepatic functionality.  Altogether, Fremanezumab is a potent drug for chronic migraine management, however, further investigation is required to assess associated long-term safety and durability.